Introduction As demand for quality but inexpensive health services increases across the globe, people are opting to use generic drugs. In the United States, high cost for the patent drugs is leading to patients using generic drugs. The American government uses varied regulations and rewards to encourage the development and sale of generic drugs. For instance, the first generic drug to enter into the market is awarded six-month market exceptionality (Grabowski, & Vernon, 2002). The development of generic drugs offers a potential opportunity to pharmaceutical companies. Unlike in Canada where there are mechanisms for controlling drug prices, the United States does not have price control mechanisms. Consequently, drugs are expensive in the United States compared to Canada. As the aging population in the United States continues swelling up, demand for healthcare services like nursing continues going up. Hence, nursing will be one of the future economically rewarding careers in the country. As demand for medical services increases across the world, more people are avoiding pursuing medical professions like doctors. Poor remuneration systems and lack of stimulating courses are some of the factors that are leading to a decline in interest in pursuing this profession. To encourage people, to pursue the profession, the government ought to come up with an attractive remuneration system and innovative courses. In the United States, there are numerous health policies that aim at ensuring that healthcare providers offer quality and affordable services. These policies are leading to transformation of healthcare organizations (Dussault, & Dubois, 2003). In future, healthcare organizations are likely to embark on pay-for-performance policy where employees will be reimbursed based on their performance. Effects of regulations on the U.S pharmaceutical industry Decision-makers in numerous countries have spurred a significant transition in the pharmaceutical industry. The creation of new policies that promote generic drugs is leading to the American pharmaceutical industry investing heavily in generic drugs, and abandoning research and development of branded drugs. Payers in the United States have held on to generic medicines by coming up with numerous policies that encourage their development and use. They promote the development and availability of generic drugs through regulatory policies such as the Bolar provisions. The provisions give room for generic producers to complete their regulatory procedures before running out of the inventor’s molecule patent. Moreover, regulations in the United States promote the development of generic drugs over branded drugs through establishing reward policies. For instance, any generic drug that first enters the market after the expiry of a patent drug is awarded six-month market inimitability (Grabowski, & Vernon, 2002). Currently, generic drug manufacturers do not go through a rigorous procedure to introduce their drugs, in the market. In 1984, the American government came up with Hatch-Waxman Act through its Food and Drug Administration department (FDA). The Act aimed at cutting down on the duration taken before a new drug is introduced to the market. Under the Act, manufacturers of generic drugs are expected to make sure that their drugs match the original ones in terms of ingr